13.09

2.51% 0.32

After Hours: 13.09

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $13.09, with a volume of 461.47K. It is up +2.51% in the last 24 hours and down -17.98% over the past month. Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Previous Close:

$12.77

Open:

$12.82

24h Volume:

461.47K

Relative Volume:

0.90

Market Cap:

$737.74M

Revenue:

Net Income/Loss:

$-153.16M

P/E Ratio:

-3.8843

EPS:

-3.37

Net Cash Flow:

$-134.48M

1W Performance:

+4.05%

1M Performance:

-17.98%

6M Performance:

-45.75%

1Y Performance:

+53.82%

1-Day Range:

$12.43

$13.11

1-Week Range:

$12.04

$13.20

52-Week Range:

$7.64

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	13.09	737.74M	0	-153.16M	-134.48M	-3.37
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

Nov 20, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Biotechnology Value Fund L.P. Expands Stake in Cullinan Therapeu - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada

Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial - Investing.com

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.

Nov 14, 2024

Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia

Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India

Nov 08, 2024

Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com

Nov 08, 2024

Nov 07, 2024

Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 07, 2024